---
schema_version: "secwatch.filing_event.v1"
accession: "0000914475-23-000062"
form_type: "8-K"
ticker: "NBIX"
cik: "0000914475"
company_name: "NEUROCRINE BIOSCIENCES INC"
filed_at: "2023-09-12T23:59:59+00:00"
generated_at: "2026-06-10T21:34:07.809076+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.95
calibrated_materiality_score: 0.95
confidence: "high"
source: SEC EDGAR
---

# Neurocrine's crinecerfont meets Phase 3 endpoint in CAH adults; FDA submission planned for 2024

## Summary
- Phase 3 CAHtalyst Adult study met primary endpoint: significant % reduction in daily glucocorticoid dose with androgen control (p<0.0001).
- Key secondary endpoint met: significant decrease in androstenedione at Week 4 vs placebo (p<0.0001).
- 63% of crinecerfont patients achieved physiologic glucocorticoid dose vs 18% on placebo (p<0.0001).
- Company to submit regulatory applications to FDA in 2024 and to EMA afterwards.
- Crinecerfont generally well-tolerated; common AEs: fatigue, headache, coronavirus infection.

## SEC filing metadata
- accession: 0000914475-23-000062
- form_type: 8-K
- ticker: NBIX
- cik: 0000914475
- company_name: NEUROCRINE BIOSCIENCES INC
- filed_at: 2023-09-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.95
- calibrated_materiality_score: 0.95
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/914475/000091447523000062/0000914475-23-000062-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/914475/000091447523000062/nbix-20230912.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000914475-23-000062
- JSON: https://secwatch.observer/filing/0000914475-23-000062.json
- Plain text: https://secwatch.observer/filing/0000914475-23-000062.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.